Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Summary of Table 2 Benchmarks The metrics in Table 2 serve as benchmarks for performance : e.g., an average specialty fill rate of 62% ( [12] ) or a first-pass GLP-1 approval of ~30% ( [3] )
Add 2,0003,500 for baseline blood work before your first dose
Private Plan Outlook Alberta Blue Cross's 2026 drug pipeline report identifies GLP-1 therapies as a major cost driver, stating that while a semaglutide generic is expected in mid-2026, overall GLP-1 therapy plan spend is unlikely to decline in future years due to growing use and continued expansion of GLP-1 therapies
GLP-1Rs exhibit broad tissue distribution, spanning the pancreas, gastrointestinal tract, cardiovascular system, and central nervous system, allowing GLP-1 RAs to impact multiple organ systems 2,3
US$ 20.50
US$ 20.88
US$ 28.62
